Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

NCT02032810 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Skin Cancer

Interventions

DRUG: Panobinostat
DRUG: Ipilimumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]